Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
IPO Year: 2021
Exchange: NASDAQ
Website: inspira-technologies.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $9.00 → $10.00 | Buy | Aegis Capital |
| 8/26/2021 | $9.00 | Buy | Aegis Capital |
6-K - QTREX Quantum Ltd. (0001837493) (Filer)
25-NSE - QTREX Quantum Ltd. (0001837493) (Subject)
6-K - QTREX Quantum Ltd. (0001837493) (Filer)
EFFECT - QTREX Quantum Ltd. (0001837493) (Filer)
POS AM - QTREX Quantum Ltd. (0001837493) (Filer)
6-K - QTREX Quantum Ltd. (0001837493) (Filer)
EFFECT - QTREX Quantum Ltd. (0001837493) (Filer)
6-K - QTREX Quantum Ltd. (0001837493) (Filer)
EFFECT - QTREX Quantum Ltd. (0001837493) (Filer)
POS AM - QTREX Quantum Ltd. (0001837493) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously
Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - QTREX Quantum Ltd. (0001837493) (Issuer)
4 - QTREX Quantum Ltd. (0001837493) (Issuer)
4 - QTREX Quantum Ltd. (0001837493) (Issuer)
4 - QTREX Quantum Ltd. (0001837493) (Issuer)
4 - QTREX Quantum Ltd. (0001837493) (Issuer)
4 - QTREX Quantum Ltd. (0001837493) (Issuer)
4 - QTREX Quantum Ltd. (0001837493) (Issuer)
4 - QTREX Quantum Ltd. (0001837493) (Issuer)
3 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Issuer)
3 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Issuer)
Fastest customizable press release news feed in the world
Ness Ziona, Israel, July 17, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that on July 14, 2026, its Board of Directors (the "Board") appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately. Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd. (NASDAQ:NNDM), where she led multidisciplinary teams spanning materials, formulations, chemistry, physics, process engineering, mechanics, software, hardware, and electronics. She also co-authored peer-reviewed IEEE research o
Nes Ziona, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure today announced that it has received a commercial purchase order from a leading international government-owned company for customized proprietary Shielded RF Monolithic components. The order expands QTREX’s commercial model into the direct supply of proprietary, application-specific components. This direct-to-customer approach serves as QTREX’s strategic blueprint for the broader quantum ecosystem, delivering tailor-made hardware precisely engineered for customers’ di
Ness Ziona, Israel, July 10, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure today announced the formation of QTREX USA, its new U.S. subsidiary serving as the Company’s dedicated platform for U.S. federal contract execution. The move follows QTREX’s recently announced operational AME deployment at a U.S. government laboratory conducting quantum computing programs, and is intended to support the Company’s federal government contracting activities in the United States. By establishing QTREX USA, the Company is building a U.S.-based commercial
Nes Ziona, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure today announced that a U.S. Government lab conducting quantum computing programs is actively operating the Company’s AME system. The operational use places the Company’s technology inside a U.S. federal quantum and advanced-microelectronics development environment, providing the lab with direct access to the unique capabilities enabled by the Company’s AME platform. The lab is one of the most prominent U.S. government research environments focused on national security
Nes Ziona, Israel, July 01, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure today announced the development of a controlled-conductivity cryogenic microwave interconnect architecture designed to reduce heat conduction while preserving microwave signal performance in quantum computing systems. The Company filed a U.S. Provisional Patent Application with the United States Patent and Trademark Office ("USPTO") and the underlying technology is patent pending. The Company’s architecture is based on the intentional use of the Wiedemann–Franz Law,
Nes Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure today announced that Dagi Ben-Noon, Chief Executive Officer of QTREX, Tal Parnas, Chairman of the Company’s Board of Directors, and members of the Company’s senior management team have informed QTREX’s Board of Directors of their intention to use personal funds to purchase up to an aggregate of 2,000,000 of the Company’s ordinary shares, no par value per share (the "Ordinary Shares") over the next 12 months from June 22, 2026, pursuant to and subject to applicable rule
Nes Ziona, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced a major technical and strategic milestone: the Company has successfully produced a cryogenic chip carrier using its proprietary single-build AME process, based on a design supplied by one of the world's largest U.S.-based technology companies developing full-stack quantum computing systems. The achievement expands QTREX's role within the quantum hardware stack into the processor-interface layer, demonstrating that the Company's AME platform can addres
Nes Ziona, June 15, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that one of the largest U.S.-based interconnect manufacturers has moved QTREX's AME system from a development environment onto its production floor following an extensive validation program. The U.S.-based manufacturer, a leading provider of high-performance interconnect solutions with established product offerings for quantum computing applications, used QTREX's AME technology to produce multiple components and to validate the related manufacturing and assem
Nes Ziona, June 09, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that the Israel Innovation Authority ("IIA") has awarded the Company an approximately $1 million grant to support the development of a purpose-built dielectric material engineered for high-density, low-loss RF signal routing in scalable superconducting quantum computing systems. QTREX's program targets one of the core scaling constraints in superconducting quantum computing: the growing need to move more RF and microwave signals through cryogenic environment
Nes Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that Mr. Tal Parnas, Chairman of the Company's Board of Directors, and Mr. Yoav Rozanovich, the Company's Chief Business Officer, will be in Boston, Massachusetts during Quantum.Tech World 2026 on June 25–26, 2026, to present functional AME-based monolithic connectivity components engineered for quantum computing systems. QTREX will conduct private, invitation-only meetings with industry leaders, research institutions and strategic partners in a dedic
Live Leadership Updates
Ness Ziona, Israel, July 17, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (NASDAQ:QTEX) ("QTREX" or the "Company"), a company focused on advancing Additively Manufactured Electronics ("AME") for quantum computing infrastructure, today announced that on July 14, 2026, its Board of Directors (the "Board") appointed Dr. Shlomit Chappel-Ram as an independent director, effective immediately. Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd. (NASDAQ:NNDM), where she led multidisciplinary teams spanning materials, formulations, chemistry, physics, process engineering, mechanics, software, hardware, and electronics. She also co-authored peer-reviewed IEEE research o
RA'ANANA, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- Inspira Technologies OXY B.H.N. Ltd (NASDAQ:IINN, IINNW)) ("Inspira Technologies" or the "Company") today announced the appointment of Mr. Yoav Rozanovich as Chief Business Officer ("CBO") of Inspira Technologies, reinforcing its commercial execution capabilities following its expansion into quantum computing connectivity and the acquisition of the Additive Manufacturing of Electronics ("AME") business from Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension"). Proven Commercial LeadershipMr. Rozanovich brings international experience across additive manufacturing, advanced electronics, and complex systems integration. From November 2021
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors of the Company (the "Board"). The Board appointed Ms. Matza to serve as an independent director of the Company until the next annual general meeting of the Company's shareholders. Ms. Matza will als
Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn
RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025. Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision. As a serial entrepreneur, Parnes has demonstrated
RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the
Dr. Nir is a clinical strategy expert with market experience RA'ANANA, Israel, May 30, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO"). Dr. Nir brings a wealth of expertise and a distinguished track record in the field of medicine and healthcare administration to the Company. As CMO, Dr. Nir will play a critical role in overseeing and guiding Inspira's medical operations and strategic initiatives. With an unwavering commitment to patient care, inn
RA'ANANA, Israel, Aug. 10, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company"), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies, today announced the appointment of Lior Amit, CPA, to the Company's board of directors. Mr. Amit has extensive business and go-to-market experience to further support Inspira's planned future deployment and market penetration of the Augmented Respiration Technology (ART) system. For more than 17 years, Mr. Amit served as the CFO of the BBR Saatchi & Saatchi advertising group in Israel, playing a vital role in the
Live finance-specific insights
The transaction includes intellectual property, customer-related assets and commercial operations, positioning the Company for the next stage of its strategy Further strategic update to follow shortly RA'ANANA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), today announced the acquisition of Nano Dimension Ltd.'s (NASDAQ:NNDM) ("Nano Dimension") AME platform. The acquired platform includes intellectual property, proprietary high-precision 3D electronic printing systems, patented software, engineering know-how, manufacturing equipment, inventory, customer-related assets, and fully equipped facilities, includin
RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent equity investment (the "Equity Investment"), positioning
RA'ANANA, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the six-month period ended June 30, 2025, and issued a business update. "The first half of 2025 represents a pivotal transformation for Inspira as we have successfully transitioned from being a development-stage company to commencing commercial execution. Our technology is now saving lives in premier U.S. hospitals while generating growing commercial interest globally," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "With $49.5 millio
Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an
Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today. On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's
The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel, June 5, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce plans to exhibit the INSPIRA™ ART100 System, recently cleared by the U.S. Food and Drug Administration ("FDA"), at the Extracorporeal Life Support Organization (ELSO) conference in Detroit, Michigan between September 29 to October 1, 2024. This event provides the Company with an opportunity to present the system in front of healthcare representa
RA'ANANA, Israel, May 30, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) (the "Company" or "Inspira") a breakthrough medical technology company, announced today that Company President, Director, and co-founder, Mr. Joe Hayon, will discuss the Company's business targets, distribution agreements and next steps in a conference call to be held at 9:00am Eastern Time on Thursday, June 20, 2024. This follows the significant milestone of receiving FDA clearance for the INSPIRA™ ART100 system, as announced on May 28, 2024. Event Details: Date: Thursday, June 20, 2024 Time: 9:00 am Eastern Time Speaker: Joe Hayon, President, Director, and Co-Founder Attendance Info
FDA Submission for approval of INSPIRA™ ART100 95% Accuracy Results for HYLA™ Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSPIRA™ ART Medical Device RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, commented, "In 2023, we achieved significant progress in diversifying our business development to ensure continuous growth, reaching very important milestones that we believ
The major milestone refers to Inspira's proprietary technology to oxygenate blood for the INSPIRA™ ART (Gen 2). This patented tech is considered by Inspira to be a game-changer and also aims to replace technologies used today by current medical device companies.Anticipated U.S. Food and Drug Administration (FDA) Clearance for INSPIRA™ ART100 (Gen 1) in the first half of 2024, to address the $1.16 Billion perfusion systems market.RA'ANANA, Israel, March 4, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President, and co-founder, Mr. Joe Hayon, p
RA'ANANA, Israel, Feb. 27, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the Company's next major milestone. The conference call is to be held at 9:00am Eastern Time on Monday, March 4, 2024. To attend the conference call, please enter: link Inspira Technologies OXY B.H.N. Ltd. Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Re
This live feed shows all institutional transactions in real time.
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)